Mesoblast Reports Ryoncil® Net Revenues of US$36M for the Quarter and US$115M for First Full Year of Product Launch

Barchart · 3d ago

Expanding indications for RYONCIL in children and adults with life-threatening inflammatory diseases

Achieved target of at least 300 Patients treated in Pivotal Phase 3 trial for Chronic Low Back Pain

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.